Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologySierra Health and Life Crysvita Coverage Update | …
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0071O

    Crysvita (burosumab-twza) — Coverage Criteria for X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in TIO

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0071O alerts

    Get alerted when Policy 2026D0071O changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity criteria, prior authorization, and coding for Crysvita (burosumab-twza) for treatment of X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) for applicable UnitedHealthcare commercial and individual exchange plans.

    Policy Summary
    Payersierra health and life
    PolicyCrysvita (burosumab-twza) — Coverage Criteria for XLH and TIO
    Policy CodePolicy 2026D0071O
    Change TypeTemplate updateapplied to UnitedHealthcare Commercial & Individual Exchange
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnostic confirmation and required labs; initial and reauthorizations are limited to 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    Policy transferred to shared template and applied to UnitedHealthcare Commercial and Individual Exchange plans; prior authorization requirements follow the member-specific plan.

    No material clinical or coverage changes beyond template update were identified in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsmax auth period
    J0584HCPCS
    ≥6 monthsmin age (XLH)
    ≥2 yearsmin age (TIO)
    <3.0 mg/dLserum phosphate

    Coverage Criteria for Crysvita (burosumab-twza)

    Initial Therapy (XLH)

    Covered when ALL of the following are met for initial XLH therapy

    XLH initial therapy criteria: Patient age 6 months or greater; diagnosis of X-linked hypophosphatemia (XLH) confirmed by one of the following: genetic testing (e.g., confirmed PHEX gene mutation in the patient or a first‑degree relative) OR elevated serum FGF23 > 30 pg/mL OR all of the following biochemical findings: serum phosphate < 3.0 mg/dL (0.97 mmol/L); serum creatinine below age‑adjusted upper limit of normal; serum 25(OH)D ≥ 16 ng/mL; prescribed by, or in consultation with, an endocrinologist or specialist experienced in metabolic bone disorders; fasting serum phosphorus below the normal range for age; dosing in accordance with FDA‑approved labeling; initial authorization for no more than 12 months.see node text

    From policy initial therapy section

    Continuation Therapy (XLH)

    Covered when ALL of the following are met for continuation (XLH)

    XLH continuation criteria: Patient has previously received burosumab; prescribed by, or in consultation with, an endocrinologist or specialist experienced in metabolic bone disorders; patient has experienced a positive clinical response to burosumab (for example: enhanced height velocity, improvement in skeletal deformities, reduction of fractures, reduction of generalized bone pain); dosing in accordance with FDA‑approved labeling; reauthorization for no more than 12 months.see node text

    From policy continuation section

    Initial Therapy (TIO)

    Covered when ALL of the following are met for initial TIO therapy

    TIO initial therapy criteria: Diagnosis of FGF23‑related hypophosphatemia in tumor‑induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors; disease cannot be curatively resected or localized; patient is age 2 years or greater; prescribed by, or in consultation with, an oncologist, an endocrinologist, or a specialist experienced in metabolic bone disorders; history of failure, contraindication, or intolerance to vitamin D analog therapy (e.g., calcitriol, paricalcitol, doxercalciferol) in combination with an oral phosphate agent (e.g., K‑Phos, K‑Phos Neutra); fasting serum phosphorus below the normal range for age; dosing in accordance with FDA‑approved labeling; initial authorization for no more than 12 months.see node text

    From policy TIO initial therapy section

    Continuation Therapy (TIO)

    Covered when ALL of the following are met for continuation (TIO)

    TIO continuation criteria: Patient has previously received burosumab; prescribed by, or in consultation with, an oncologist, an endocrinologist, or a specialist experienced in metabolic bone disorders; patient has experienced a positive clinical response to burosumab (e.g., improved skeletal findings, reduced fractures or bone pain); dosing in accordance with FDA‑approved labeling; reauthorization for no more than 12 months.see node text

    From policy TIO continuation section

    This policy summarizes the clinical coverage framework for Crysvita (burosumab-twza) in FGF23-mediated hypophosphatemic disorders. It defines the medical necessity expectations for initial and continuation therapy in X-linked hypophosphatemia (XLH) and for initial and continuation therapy in tumor‑induced osteomalacia (TIO). The policy aligns coverage determinations with documented diagnosis, age thresholds, biochemical data, prescriber specialty involvement, and dosing consistent with the FDA label. References to member-specific benefit plan terms, federal or state mandates, and Medicare program requirements are incorporated where applicable.

    FDA approval and the drug’s labeled indications are provided here for informational context only. FDA approval alone is not a basis for coverage; coverage decisions require that the member’s clinical presentation and submitted documentation meet the policy’s medical necessity criteria and any applicable member benefit or regulatory requirements.

    Coverage decisions under this policy depend on the documentation supplied and the member’s specific benefit terms. Providers must submit the clinical records and laboratory data specified in the coverage criteria; requests lacking the required diagnostic confirmation, relevant labs, or documentation of prior therapy where required may be denied. The inclusion of procedure or diagnosis codes in this policy is for reference only and does not guarantee coverage or payment—always verify the member’s benefit document and any applicable state mandates before assuming coverage.

    Coding and Billing Codes

    Covered HCPCSHCPCSCovered
    J0584Injection, burosumab-twza, 1 mg
    Relevant diagnosis codes (reference)ICD-10
    E83.31Familial hypophosphatemia
    M83.8Other adult osteomalacia
    inv-10: Serum phosphate — biochemical threshold value used in criteria
    Serum phosphate thresholdFasting serum phosphate < 3.0 mg/dL (0.97 mmol/L)
    Supporting lab contextUsed as part of biochemical criteria for initial XLH diagnosis when genetic testing or elevated FGF23 not available
    Clinical trial concordanceClinical studies enrolled children with fasting serum phosphorus lower than 0.97 mmol/L (3.0 mg/dL)

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initiation of burosumab (Crysvita). Initial and reauthorization approvals are limited to no more than 12 months.

    • Initial authorization: ≤ 12 months
    • Reauthorization: ≤ 12 months
    • Dosing must follow FDA labeling
    Denial Risk

    Medicare Part B and CMS Compliance

    For Medicare Advantage reviews, ensure compliance with Medicare Part B/NCDs/LCDs/LCAs where applicable. Part B rules (including "incident to" requirements and whether a drug is usually self‑administered) may affect coverage. Preferred therapy criteria may be governed by Medicare Part B step therapy programs — consult CMS guidance and the Medicare Advantage Medical Policy as needed.

    Background and Clinical Context

    X-linked hypophosphatemia (XLH) is a heritable renal phosphate‑wasting disorder caused by elevated FGF23, resulting in chronic hypophosphatemia and impaired bone mineralization. The therapeutic mechanism of burosumab is neutralization of excess FGF23 to increase renal phosphate reabsorption and raise serum phosphate toward age‑appropriate ranges. In children the treatment goal focuses on correction of rickets and improved growth velocity; in adults the focus is on reducing bone pain, improving mobility, and promoting fracture or pseudofracture healing. For tumor‑induced osteomalacia (TIO), burosumab is used when the phosphaturic tumor cannot be localized or curatively resected and the patient has FGF23‑mediated hypophosphatemia.

    Definitions

    inv-20: XLH — Definition of X-linked hypophosphatemia (FGF23-mediated disorder)
    DefinitionX-linked hypophosphatemia (XLH) is a heritable disorder of renal phosphate transport associated with elevated serum FGF23 and resulting hypophosphatemia and abnormal bone mineralization.
    PathophysiologyElevated FGF23 causes renal phosphate wasting and low serum phosphate, leading to rickets/osteomalacia in children and bone pain or fractures in adults.
    Diagnostic cluesDiagnosis may be confirmed by PHEX gene mutation in the patient or a first-degree relative, elevated FGF23, or characteristic biochemical findings including low serum phosphate.
    inv-21: TIO — Definition of Tumor-induced osteomalacia (FGF23-related hypophosphatemia due to tumor)
    DefinitionTumor-induced osteomalacia (TIO) is an acquired paraneoplastic syndrome in which phosphaturic mesenchymal tumors ectopically produce FGF23, causing FGF23-related hypophosphatemia and impaired bone mineralization.
    Policy Summary
    Payersierra health and life
    PolicyCrysvita (burosumab-twza) — Coverage Criteria for XLH and TIO
    Policy CodePolicy 2026D0071O
    Change TypeTemplate updateapplied to UnitedHealthcare Commercial & Individual Exchange
    Effective DateMay 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnostic confirmation and required labs; initial and reauthorizations are limited to 12 months.
    SourceLink
    On This Page
    Coverage Criteria for Crysvita (burosumab-twza)Coding and Billing CodesProvider Actions, Prior Authorization, and DocumentationBackground and Clinical ContextDefinitions
  1. Check CMS NCDs/LCDs/LCAs: https://www.cms.gov/medicare-coverage-database/new-search/search.aspx
  2. Refer to Medicare Benefit Policy Manual, Chapter 15, §50
  3. Documentation Required

    Required Clinical Documentation

    Submit documentation that confirms the diagnosis, relevant labs, prior therapies, prescriber specialty, and age as applicable. Missing required documentation may lead to denial.

    • Diagnosis confirmation: genetic testing showing PHEX mutation OR elevated serum FGF23 > 30 pg/mL OR biochemical profile (serum phosphate < 3.0 mg/dL; serum creatinine below age‑adjusted ULN; serum 25(OH)D ≥ 16 ng/mL)
    • Prescriber: prescribed by or in consultation with an endocrinologist, oncologist, or specialist experienced in metabolic bone disorders (per indication)
    • Laboratory data: fasting serum phosphorus below age‑specific normal range; serum creatinine and 25(OH)D levels as above
    • Age: patient age ≥ 2 years for TIO indication
    • Clinical response for continuation: documentation of positive clinical response (e.g., improved height velocity, improved skeletal deformities, fewer fractures, reduced generalized bone pain)
    Note

    Member‑Specific Benefit Verification

    Verify member benefits and any applicable federal or state mandates before authorizing therapy. The member specific benefit plan document governs and may impose different coverage terms.

    • Confirm coverage under the member's specific plan documents
    • Check for state or federal mandates that may affect coverage
    • This policy assists interpretation of UnitedHealthcare standard benefit plans but the member specific benefit plan controls
    Step Therapy

    Step Therapy Requirement for TIO

    For tumor‑induced osteomalacia (TIO), document failure, contraindication, or intolerance to combination therapy with a vitamin D analog (e.g., calcitriol, paricalcitol, doxercalciferol) plus an oral phosphate agent (e.g., K‑Phos®, K‑Phos Neutra®) prior to initiating burosumab.

    • Record prior use and outcome of vitamin D analog + oral phosphate therapy
    • If contraindication or intolerance is cited, provide supporting clinical rationale and documentation
    • For Medicare reviews, refer to CMS/Medicare Part B step therapy guidance as applicable
    Tumor characteristicsTypically benign, small, slow-growing polymorphous mesenchymal neoplasms that secrete FGF23 and other phosphaturic proteins.
    Treatment contextBurosumab is evaluated for TIO when the tumor cannot be curatively resected or cannot be localized; clinical trials enrolled adults with non-resectable or unlocalized tumors.
    inv-22: FGF23-blocking antibody indicated for XLH and certain TIO cases per FDA prescribing information — Crysvita indication summary
    AgentCrysvita (burosumab) — an FGF23‑blocking antibody indicated by FDA for XLH and certain TIO cases.
    XLH indication and ageIndicated for treatment of X-linked hypophosphatemia in adult and pediatric patients 6 months of age and older.
    TIO indication and ageIndicated for treatment of FGF23‑related hypophosphatemia in tumor‑induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.